|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o 4-Antibody AG, of Basel, Switzerland, closed a CHF6 million (US$4.9 million) Series A financing, which was provided by existing investors, including Biomedinvest AG, Grazia Equity, Life Science Partners and Mulligan Biocapital. Proceeds will be used to develop the company's internal pipeline and partnership opportunities relating to its work on fully human antibodies. 4-Antibody also appointed Sijmen de Vries as the new CEO.
o Akesis Pharmaceuticals Inc., of San Diego, said a study published in Diabetes Care demonstrates the positive effects of the trace element chromium when combined with a sulfonylurea drug in Type II diabetes patients, showing an improved ...
Related newspaper, magazine, and journal articles:
|